Eiger BioPharmaceuticals News

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Strukturierte Produkte

Aktion

Portfolio

Watchlist

01.04.24	Metabolic Diseases-Focused Eiger BioPharmaceuticals Files For Bankruptcy, Stock Nosedives (Benzinga)
09.11.23	Eiger BioPharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update (PR Newswire)
13.09.23	Eiger To Discontinue Peginterferon Lambda Trial In CHD Patients; Stock Down In Premarket (RTTNews)
12.09.23	Eiger to Discontinue Phase 3 LIMT-2 Trial of Peginterferon Lambda in Patients with Chronic Hepatitis Delta (PR Newswire)
05.09.23	Eiger BioPharmaceuticals to Present at H.C. Wainwright 25th Annual Global Investment Conference (PR Newswire)
14.08.23	Eiger BioPharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update (PR Newswire)
29.06.23	Eiger BioPharmaceuticals to Focus on Metabolic Diseases with Avexitide; David Apelian Takes Helm as CEO (PR Newswire)
28.06.23	Eiger BioPharmaceuticals to Host Business Update Call Tomorrow (PR Newswire)
11.05.23	Eiger BioPharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business Update (PR Newswire)
13.04.23	Eiger BioPharmaceuticals Strengthens Management Team with New Appointments (PR Newswire)
16.03.23	Eiger BioPharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update (PR Newswire)
08.02.23	New England Journal of Medicine Publishes Positive Phase 3 TOGETHER Results with Peginterferon Lambda in COVID-19 (PR Newswire)
02.01.23	ROSEN, A GLOBALLY RECOGNIZED FIRM, Encourages Eiger BioPharmaceuticals, Inc. Investors with Losses to Secure Counsel Before Important January 9 Deadline in Securities Class Action - EIGR (PR Newswire)
23.12.22	ROSEN, A GLOBALLY RECOGNIZED FIRM, Encourages Eiger BioPharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - EIGR (PR Newswire)
16.12.22	ROSEN, A TOP RANKED LAW FIRM, Encourages Eiger BioPharmaceuticals, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - EIGR (PR Newswire)
10.12.22	EIGR INVESTOR NEWS: ROSEN, NATIONAL TRIAL COUNSEL, Encourages Eiger BioPharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - EIGR (PR Newswire)
08.12.22	Eiger Announces Both Lonafarnib-based Treatments in Pivotal Phase 3 D-LIVR Trial in Hepatitis Delta Virus (HDV) Achieved Statistical Significance Against Placebo in Composite Primary Endpoint (PR Newswire)
07.12.22	Eiger BioPharmaceuticals to Host Conference Call to Discuss Phase 3 D-LIVR Study Results of Lonafarnib-based Treatments in Hepatitis Delta Virus (HDV) on Thursday, December 8, 2022 (PR Newswire)
03.12.22	ROSEN, NATIONAL TRIAL LAWYERS, Encourages Eiger BioPharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - EIGR (PR Newswire)
24.11.22	ROSEN, SKILLED INVESTOR COUNSEL, Encourages Eiger BioPharmaceuticals, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - EIGR (PR Newswire)
17.11.22	ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Eiger BioPharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - EIGR (PR Newswire)
11.11.22	ROSEN, SKILLED INVESTOR COUNSEL, Encourages Eiger BioPharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - EIGR (PR Newswire)
08.11.22	Eiger BioPharmaceuticals to Participate in Upcoming Investor Conferences (PR Newswire)
03.11.22	Eiger BioPharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update (PR Newswire)
02.11.22	Ausblick: Eiger BioPharmaceuticals zieht Bilanz zum jüngsten Jahresviertel (finanzen.net)
24.10.22	Eiger BioPharmaceuticals to Host Conference Call for Third Quarter 2022 Financial Results and Business Update on Thursday, November 3 (PR Newswire)
11.10.22	Eiger BioPharmaceuticals to Present at the H.C. Wainwright Third Annual Hepatitis B Virus (HBV) Virtual Conference (PR Newswire)
05.10.22	Eiger BioPharmaceuticals Provides Update on Plans for Emergency Use Authorization Application Following FDA Feedback (PR Newswire)
22.09.22	Eiger BioPharmaceuticals to Present at the 2022 Ladenburg Thalmann Healthcare Conference (PR Newswire)
06.09.22	Eiger: FDA Ready To Consider Any New Data To Support EUA Application For Peginterferon Lambda (RTTNews)
06.09.22	Eiger BioPharmaceuticals Provides Update on Status of Planned Peginterferon Lambda COVID-19 Emergency Use Authorization Application (PR Newswire)
01.09.22	Eiger BioPharmaceuticals to Participate in Three Upcoming Investor Conferences (PR Newswire)
04.08.22	Eiger BioPharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update (PR Newswire)
04.08.22	Ausblick: Eiger BioPharmaceuticals präsentiert Bilanzzahlen zum jüngsten Jahresviertel (finanzen.net)
28.07.22	Eiger BioPharmaceuticals to Host Conference Call for Second Quarter 2022 Financial Results and Business Update on Thursday, August 4 (PR Newswire)
20.07.22	Eiger Receives European Approval for Zokinvy® (lonafarnib) for Hutchinson-Gilford Progeria Syndrome and Processing-Deficient Progeroid Laminopathies (PR Newswire)
18.07.22	Eiger Appoints Senior Human Resources and Organizational Executive Lisa Kelly-Croswell to Board of Directors (PR Newswire)
27.06.22	Eiger BioPharmaceuticals Announces Results from Multiple Presentations at the European Association for the Study of the Liver (EASL) International Liver Congress™ 2022 (PR Newswire)
13.06.22	Eiger BioPharmaceuticals Announces New Data Supporting Broader Potential of Avexitide in Patients with Post-Bariatric Hypoglycemia and Hyperinsulinemic Hypoglycemia After Gastrointestinal Surgeries (PR Newswire)
08.06.22	Eiger BioPharmaceuticals Announces Multiple Presentations at the European Association for the Study of the Liver (EASL) International Liver Congress™ 2022 (PR Newswire)
07.06.22	Eiger BioPharmaceuticals Enters into $75M Term Loan Agreement and $5M Stock Purchase Agreement with Innovatus Capital Partners to Refinance Existing Debt Facility and Further Strengthen Cash Posit... (PR Newswire)
03.06.22	Eiger BioPharmaceuticals to Present at the Jefferies Global Healthcare Conference (PR Newswire)
20.05.22	Eiger Receives Positive CHMP Opinion for Zokinvy as a Treatment for Hutchinson-Gilford Progeria Syndrome and Processing-Deficient Progeroid Laminopathies (PR Newswire)
10.05.22	Eiger BioPharmaceuticals and AnGes Announce Exclusive Partnership for Regulatory Approval and Commercialization of Zokinvy® (lonafarnib) in Japan (PR Newswire)
05.05.22	Eiger BioPharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update (PR Newswire)
30.04.22	Eiger BioPharmaceuticals Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4) (PR Newswire)
25.04.22	Eiger Announces Publication of Positive Phase 2 Results of Avexitide in Children with Congenital Hyperinsulinism and Initiation of Phase 3 Program (PR Newswire)
21.04.22	Eiger BioPharmaceuticals to Host Conference Call for First Quarter 2022 Financial Results and Business Update on Thursday, May 5 (PR Newswire)
18.04.22	Eiger BioPharmaceuticals Strengthens Leadership Team with New Executive Appointments (PR Newswire)
17.03.22	Eiger's Single-dose Peginterferon Lambda for COVID-19 Reduced Risk of Hospitalization or ER Visits by 50% in a Predominantly Vaccinated Population in Phase 3 TOGETHER Study (PR Newswire)

Newssuche

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Part Grp Hldg	1’263.50	2.89 %	K V
Sonova Hldg	312.10	2.66 %	K V
Novartis	93.68	2.32 %	K V
Geberit	526.80	1.97 %	K V
Roche Hldg G	254.30	1.27 %	K V
Kuehne+Nagel Int	209.50	0.72 %	K V
UBS Group	28.30	0.57 %	K V
Givaudan	3’933.00	0.36 %	K V
Nestle	76.00	0.05 %	K V
Lonza Grp	521.40	-0.04 %	K V